Hepion Pharmaceuticals is a biopharmaceutical company focused primarily on the development of drug therapy for treatment of chronic fibrosis related diseases. The main therapeutic approach specifically targets the disease mechanism related to fibrosis as well as, inflammation and shows potential for the treatment of non-alcoholic steatohepatitis, hepatocellular carcinoma, viral hepatitis, and other fibrotic diseases. Co.'s cyclophilin inhibitor, rencofilstat, is being developed to address multiple pathologies related to advanced fibrotic diseases. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of fibrosis. We show 20 historical shares outstanding datapoints in our HEPA shares outstanding history coverage, used to compute HEPA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HEPA market cap history over the course of time is important for investors
interested in comparing HEPA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HEPA versus a peer is one thing; comparing
HEPA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HEPA can fluctuate over the course of history.
With this page we aim to empower investors researching HEPA by allowing them to research the HEPA market cap history. |
Free HEPA Email Alerts:
Video: The Importance of Market Cap
